Press

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

Feb 24 • 5 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business. “With our end-of-phase II meeting now scheduled with the FDA, we…

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

Feb 23 • 6 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has successfully completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary…

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

Feb 22 • 4 min read

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a neuroscience company focused on psychedelic-assisted therapies for mental health, is pleased to share the analysis of Phase I data from the combined Phase I/IIa clinical trial of SPL026 with psychotherapy for the treatment of Major Depressive Disorder. In the dose-escalating, placebo-controlled Phase I study, 32 healthy psychedelic…

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Feb 21 • 4 min read

Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that Nova Mentis successfully completed an oral microdose psilocybin preclinical study, in the laboratory of Dr. Viviana Trezza, Rome Tre University, Rome, Italy. The results exceeded all expectations with the findings that a…

Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules

Feb 18 • 2 min read

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF), a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, strengthened its intellectual property portfolio and pipeline for the treatment of addictions with the filing of a patent application for a new chemical series of entactogen-like molecules. Entactogen-like molecules are a class of psychoactive substances that…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435